{"title": "Epidemiological characteristics of 1212 COVID-19 patients in Henan, China", "doi": "10.1101/2020.02.21.20026112", "citation_id": "2020.02.21.20026112v2", "date": "2020-02-25", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.21.20026112", "abstract": "<p>Based on publicly released data for 1212 patients, we investigated the epidemiological characteristics of COVID-19 in Henan of China. The following findings are obtained: 1) COVID-19 patients in Henan show gender (55% vs 45%) and age (81% aged between 21 and 60) preferences, possible causes were explored; 2) Statistical analysis on 483 patients reveals that the estimated average, mode and median incubation periods are 7.4, 4 and 7 days; Incubation periods of 92% patients were no more than 14 days; 3) The epidemic of COVID-19 in Henan has undergone three stages and showed high correlations with the numbers of patients that recently return from Wuhan; 4) Network analysis on the aggregate outbreak phenomena of COVID-19 revealed that 208 cases were clustering infected, and various people9s Hospital are the main force in treating patients. The related investigations have potential implications for the prevention and control of COVID-19.</p>", "twitter_description": "Based on publicly released data for 1212 patients, we investigated the epidemiological characteristics of COVID-19 in Henan of China. The following findings are obtained: 1) COVID-19 patients in Henan show gender (55% vs 45%) and age (81% aged between 21 and 60) preferences, possible causes were explored; 2) Statistical analysis on 483 patients reveals that the estimated average, mode and median incubation periods are 7.4, 4 and 7 days; Incubation periods of 92% patients were no more than 14 days; 3) The epidemic of COVID-19 in Henan has undergone three stages and showed high correlations with the numbers of patients that recently return from Wuhan; 4) Network analysis on the aggregate outbreak phenomena of COVID-19 revealed that 208 cases were clustering infected, and various people's Hospital are the main force in treating patients. The related investigations have potential implications for the prevention and control of COVID-19.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Clinical Trial\n\nThis is an epidemiological study on patients with COVID-19 in Henan, China\n\n### Funding Statement\n\nThis work was supported by the National Natural Science Foundation of China (Grant Nos. 61773153, 61773175, 61573262). The Supporting Plan for Scientific and Technological Innovative Talents in Universities of Henan Province (Grant No. 20HASTIT025), and the Training Plan of Young Key Teachers in Colleges and Universities of Henan Province (Grant No. 2018GGJS021). Partly supported by the supporting grant of Bioinformatics Center of Henan University (Grant No. 2018YLJC03).\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nData are publicly available from the all levels of CDCs' websites in Henan of China", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.21.20026112v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.21.20026112v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.21.20026112v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/25/2020.02.21.20026112.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.21.20026112v2", "access_rights": "restricted", "authors": ["Pei Wang", "Junan Lu", "Yanyu Jin", "Mengfan Zhu", "Lingling Wang", "Shunjie Chen"]}